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Context: Prader–Willi syndrome (PWS) is associated with several hypothalamic-pituitary hormone 
deficiencies. There is no agreement on the prevalence of central adrenal insufficiency (CAI) in adults 
with PWS. In some countries, it is general practice to prescribe stress-dose hydrocortisone during 
physical or psychological stress in patients with PWS. Side effects of frequent hydrocortisone use are 
weight gain, osteoporosis, diabetes mellitus, and hypertension—already major problems in adults 
with PWS. However, undertreatment of CAI can cause significant morbidity—or even mortality.
Objective: To prevent both over- and undertreatment with hydrocortisone, we assessed the 
prevalence of CAI in a large international cohort of adults with PWS. As the synacthen test shows 
variable results in PWS, we only use the metyrapone test (MTP) and insulin tolerance test (ITT).
Design: Metyrapone test or ITT in adults with PWS (N = 82) and review of medical files for 
symptoms of hypocortisolism related to surgery (N = 645).
Setting: Outpatient clinic.
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Patients or Other Participants: Eighty-two adults with genetically confirmed PWS.
Main Outcome Measure: For MTP, 11-deoxycortisol > 230 nmol/L was considered sufficient. For 
ITT, cortisol > 500 nmol/L (Dutch, French, and Swedish patients) or > 450 nmol/L (British patients) 
was considered sufficient.
Results: Central adrenal insufficiency was excluded in 81 of 82 patients. Among the 645 
patients whose medical files were reviewed, 200 had undergone surgery without perioperative 
hydrocortisone treatment. None of them had displayed any features of hypocortisolism.
Conclusions: Central adrenal insufficiency is rare (1.2%) in adults with PWS. Based on these 
results, we recommend against routinely prescribing hydrocortisone stress-doses in adults with 
PWS. (J Clin Endocrinol Metab 105: 1–9, 2020)
Freeform/Key Words:  Prader–Willi syndrome, central adrenal insufficiency, hypocortisolism, 
insulin tolerance test, metyrapone test
P rader–Willi Syndrome (PWS) is a rare and complex genetic disorder caused by the lack of expression of 
paternally inherited genes in the PWS region on chromo-
some 15q11-q13 (1). Apart from intellectual disability, 
sleep-related disorders and hypotonia, PWS is associated 
with hypothalamic dysfunction (1, 2), resulting in an in-
satiable appetite, disturbed thermoregulation, abnormal 
pain perception, and pituitary hormone deficiencies 
(2–4). In adults with PWS, growth hormone (GH) defi-
ciency is reported in 0–38% (5, 6) and hypothyroidism 
in 13.6% (7) of patients. Hypogonadism is present in 
the majority of patients with PWS and can be either pri-
mary or central (8). There is no agreement on the preva-
lence of deficiencies in other pituitary hormones.
Mortality is high among patients with PWS (3% an-
nual death rate across all ages) and death is often un-
expected (9). It has been suggested that sudden death 
in patients with PWS might partly be explained by cen-
tral adrenal insufficiency (CAI): an inadequate (increase 
in) cortisol production by the adrenal glands due to the 
insufficient secretion of adrenocorticotropic hormone 
(ACTH) or corticotropin-releasing hormone (CRH) by 
the pituitary gland or hypothalamus, respectively. If left 
untreated, CAI can result in an adrenal crisis, which is 
life-threatening. During crisis, a drop in blood pressure, 
organ failure, and/or mental alteration can lead to hos-
pitalization or even treatment in the Intensive Care Unit.
Replacement with synthetic cortisol (hydrocorti-
sone) is therefore advocated if patients have symptoms 
of CAI (10), which include muscle weakness, fatigue, 
and weight loss. However, these symptoms are unreli-
able in PWS. Muscle weakness and fatigue are common 
in PWS (11) and weight loss is not unusual, as most in-
dividuals with PWS are on a diet. In some countries, it 
is general practice to administer hydrocortisone during 
stressful situations, such as surgery, illness, or intense 
psychological stress (10, 12). However, stress and illness 
are often hard to define in individuals with PWS, as 
hypothalamic dysfunction reduces pain perception and 
the ability to mount a fever (11). Furthermore, the be-
havioral phenotype of PWS is characterized by frequent 
temper outbursts, causing psychological stress.
These uncertainties lead to frequent administra-
tion of hydrocortisone in people with PWS. Side ef-
fects of frequent overuse of hydrocortisone are weight 
gain, osteoporosis, diabetes mellitus, and hypertension 
(13), already major problems in adults with PWS (14). 
Ideally, hydrocortisone should only be prescribed when 
it is absolutely necessary.
There is no agreement on the prevalence of CAI and on 
the need for hydrocortisone use in adults with PWS, due 
to the use of different test methods and the fact that most 
studies involved children, not adults (10, 12, 15–21). In 
a previous Dutch study among 25 children with PWS, 
15 (60%) were diagnosed with CAI based on ACTH 
levels during single-dose metyrapone tests (sMTP) using 
an ACTH cutoff < 33 pmol/L (12). However, the use 
of ACTH levels in the evaluation of the hypothalamic-
pituitary-adrenal (HPA) axis has been debated, as it can 
lead to false-positive results (22). Studies using other test 
methods to diagnose CAI found much lower prevalences 
or even total absence of CAI in children (10, 16–21) and 
adults (15, 18). However, most studies used the synacthen 
test, which is adequate for diagnosing primary adrenal in-
sufficiency (PAI) but less reliable for diagnosing CAI (23).
As both untreated CAI and overtreatment with hydro-
cortisone can have severe adverse consequences for the 
patient, it is important to know the true prevalence of 
CAI in adults with PWS. National PWS experts from 7 
countries have collaborated to define the prevalence of 
CAI in 82 adults with PWS, which is a large group for 
such a rare disorder. As the use of less sensitive diag-
nostic tests causes uncertainty, we only report the results 
from the 2 most robust tests for diagnosis of CAI: the in-
sulin tolerance test (ITT) and multiple-dose metyrapone 
test (MTP). Apart from collecting MTP and ITT data, 
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we reviewed the medical records of 645 adults with PWS 
to define the true prevalence of CAI in adults with PWS.
Methods
All participating centers obtained approval from ethics 
committees and/or individual patients to retrospectively col-
lect data on the ITT and MTP performed in adults with PWS.
Part A: diagnosis of CAI
The HPA axis was tested in 56 Dutch, 10 French, 10 
British, and 6 Swedish adults with PWS as part of regular 
patient care. Part of the data on the 6 Swedish patients has 
been published previously (18). Eight adults with PWS did not 
undergo ITT/MTP, because they used daily hydrocortisone 
based on synacthen test failure or extremely low baseline cor-
tisol. Although diagnosis of CAI was not based on MTP or 
ITT, the patients were not retested by MTP or ITT due to be-
havioral issues or for other patient-related reasons.
Metyrapone test procedure. Patients were hospitalized for 2 
consecutive days. On day one, after a 10- to 12-hour overnight 
fast, blood samples for ACTH and cortisol were taken at 7:45 
am, and metyrapone (750 mg, Laboratoire HRA Pharma, Paris, 
France) was administered orally at 8:00 am, 12:00 pm, 4:00 pm, 
8:00 pm, 12:00 am, and 4:00 am. Patients were fed at 6:00 pm. 
On day 2, blood samples for cortisol and 11-deoxycortisol were 
taken at 7:45 am after a 10- to 12-hour overnight fast. Blood 
samples were taken through a peripheral intravenous catheter. 
Patients were recumbent from 7:00 am until the blood collection 
was completed. To ensure appropriate cortisol suppression, we 
used a day 2 morning cortisol cutoff of 200 nmol/L.
To assess the clinical value of ACTH during MTP in the 
diagnosis of CAI, ACTH was also measured. Delta ACTH was 
defined as the difference between ACTH at the start of the test 
(baseline ACTH) and the peak ACTH level.
Insulin tolerance test procedure. Patients were hospitalized 
for 1 day. After a 10- to 12-hour overnight fast, short-acting 
insulin (Insuman Rapid®, Actrapid®, 0.15U/kg) was admin-
istered at t = 0 in order to achieve hypoglycaemia (blood glu-
cose ≤ 2.2  mmol/L). Blood samples for cortisol and glucose 
were taken at t = 0, 30, 60, and 90 minutes through a periph-
eral intravenous catheter. In Dutch and British patients, ACTH 
was also measured. Additional insulin (dose based on the ac-
tual glucose level and weight of the patient) was administered 
if the glucose level was ≥ 2.2 mmol/L at t = 60, unless patients 
showed severe clinical signs of hypoglycaemia, and blood sam-
ples were taken at t = 80, 90, 100, 120, and 150 minutes. The 
patients were recumbent from the start of the study until the 
final blood sample was collected. If women were taking oral 
estrogens, these were stopped at least 6 weeks before the ITT 
to avoid artefactual elevations of measured cortisol due to in-
creased levels of cortisol-binding globulin. Corticosteroids were 
ceased at least 1 week before testing, both for MTP and ITT.
Assays. Adrenocorticotropic hormone and cortisol levels were 
measured with Siemens Immulite 2000XPi (Dutch patients; 
British patients for all ACTH measurements and for cortisol 
before August 2010), chemiluminescence immunoassay Abbott 
Architect i2000 (British patients for cortisol measurements after 
August 2010, to which all British cortisol results were aligned 
based on a field comparison study), immunochimiluminescence 
Roche  Cobas (French patients), or electrochemiluminescence 
immunoassay Elecsys, Roche (Swedish patients). Blood glu-
cose was measured with Roche Cobas C (Dutch, French, and 
Swedish patients) and Abbott Architect i2000 (British patients). 
11-deoxycortisol was measured with UPLC-MSMS (Waters 
TQS, Etten-Leur, the Netherlands) in all patients. For MTP, 
11-deoxycortisol > 200 nmol/L (>230 nmol/L or 7.9 µg/dL in 
the Dutch center due to harmonization) was considered suffi-
cient (24). For Dutch, French, and Swedish patients who under-
went ITT, cortisol > 500 nmol/L (18.1 µg/dL) was considered 
sufficient, whereas for British patients cortisol > 450  nmol/L 
(16.3  µg/dL) was considered sufficient (after alignment of 
the previous > 500  nmol/L [18.1 µg/dL] cutoff from Siemens 
Immulite 2000 assay to the Abbott Architect i2000 assay). The 
reference range for baseline cortisol was 200–700 nmol/L.
Part B: patient file review
We reviewed the medical files of all 645 adult patients with 
PWS who visited the centers participating in the International 
Network for Research, Management & Education on Adults 
with PWS: Italy (240), France (110), the Netherlands (110), 
Australia (60), Spain (45), Sweden (38), and the UK (42). We 
collected clinical data to determine rates and means of diag-
nosis of CAI, the number of patients on continuous hydrocor-
tisone treatment, and the number of patients that underwent 
surgery with and without stress doses of hydrocortisone.
Part C: literature review
We performed a PubMed search and reviewed the med-
ical literature for studies that have assessed adrenal function 
in > 1 patient by dynamic testing of the HPA axis. We used the 
following search strategy: “Prader–Willi Syndrome” [Mesh] 
AND “adrenal” [All Fields].
Data analysis
Data were analyzed with R version 3.6.0. Continuous data 
are presented as median (range) and categorical data are pre-
sented as count. We calculated Spearman’s rho for the analysis 
of correlations. P-values of < 0.05 were considered significant.
Role of the funding source
For this study, we received financial support from CZ fund. 
CZ fund had no role in the study design; in the collection, ana-
lysis, and interpretation of data; in writing the report; or in the 
decision to submit the paper for publication.
Results
Eighty-two patients (46 males, 36 females) were tested 
for CAI. Forty-six patients underwent MTP and 36 pa-
tients underwent ITT. None of the patients underwent 
both tests. Patient characteristics are shown in Table 1.
Multiple-dose metyrapone test
The results of the MTP are shown in Table  2 and 
Fig. 1. All patients’ 11-deoxycortisol levels were above 
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230 nmol/L (median 440.1, range 247.8–694.0 nmol/L). 
In 2 patients, the day 2 morning cortisol was above the 
cutoff of 200  nmol/L, namely 213 and 211  nmol/L. 
Although this was suggestive of inadequate inhibition 
of 11-β hydroxylase, it still provoked an adequate in-
crease of 11-deoxycortisol (298.2 and 425.3 nmol/L at 
day 2), confirming that the function of the HPA axis 
was normal.
There was no significant relation between baseline 
cortisol and 11-deoxycortisol after metyrapone admin-
istration (ρ = 0.16; P = 0.28), as shown in Fig. 1A. All 
patients with a baseline cortisol below the lower refer-
ence limit of 200 nmol/L (lowest: 126.0 nmol/L) had a 
sufficient 11-deoxycortisol response.
The median (range) ACTH level after metyrapone 
administration was 37.7 (2.8–132.0) pmol/L. The 
ACTH level during MTP correlated poorly with 
11-deoxycortisol level (ρ = 0.35; P = 0.02; Fig. 1B), as 
did delta ACTH (ρ = 0.38; P = 0.01).
Insulin tolerance test
The results of the ITT are shown in Table 3. Only 
2 patients did not reach the target hypoglycaemia 
of ≤ 2.2  mmol/L as at near-target glucose levels 
(2.6 mmol/L in 1 patient and 2.4 mmol/L in the other); 
they already had clinical signs of severe hypoglycaemia 
(somnolence, reduced arousal, and increased perspir-
ation) such that it was considered unethical to admin-
ister more insulin.
During the ITT, 35 of 36 patients (including the 2 
who did not reach hypoglycaemia of ≤ 2.2  mmol/L) 
had peak cortisol levels above the cutoff of 500 nmol/L. 
Only 1 French patient, who had no physical signs of 
CAI but was tested because of the transition from pedi-
atric to adult care, had a suboptimal peak cortisol level 
of 494 nmol/L. He was prescribed hydrocortisone for 
use during physical stress. Since it was very difficult to 
obtain intravenous access in this patient, the ITT was 
not repeated.
The peak cortisol correlated poorly with peak ACTH 
(ρ = -0.04; P = 0.91) and delta ACTH during ITT 
(ρ = 0.05; P = 0.88).
Reviewing medical files
We reviewed the medical files of 645 adult patients 
with PWS. Six French, 1 Australian, and 1 British pa-
tient used daily hydrocortisone based on a previous 
Table 2. Results of the multiple-dose metyrapone test
 
Before a After b Delta c CAI Cutoff d
ACTH 
(pmol/L)
Cortisol 
(nmol/L)
ACTH 
(pmol/L)
Cortisol 
(nmol/L)
11-deoxycortisol 
(nmol/L)
ACTH 
(pmol/L)
11-deoxycortisol 
(nmol/L)
Median 3.5 325.5 37.7 70.0 440.1 33.4 <230
Range 1.3–16.2 126.0–764.0 2.8–132.0 28.0–213.0 e 247.8–694.0 -1.4–118.9
Abbreviation: CAI, central adrenal insufficiency.
a Before metyrapone administration. b After metyrapone administration. c Increase in ACTH after metyrapone administration. d 11-deoxycortisol 
cutoff for diagnosis of CAI. e In 2 patients, the day 2 morning cortisol was above the cutoff of 200 nmol/L, namely 213 and 211 nmol/L. Although 
this was suggestive of inadequate inhibition of 11-β hydroxylase, it still provoked an adequate increase of 11-deoxycortisol (298.2 nmol/L and 425.3 
at day 2), showing function of the HPA axis was normal.
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Figure 1. Results of the multiple-dose MTP in patients with Prader–
Willi syndrome. N = 46. A: Relation between baseline cortisol (nmol/L) 
and 11-deoxycortisol (nmol/L). Spearman’s rho was 0.16 (P = 0.28). 
Even patients with low baseline cortisol had normal 11-deoxycortisol 
levels. B: Relation between ACTH (pmol/L) after metyrapone 
administration and 11-deoxycortisol (nmol/L). Spearman’s rho was 
0.35 (P = 0.02). The dotted line represents the cutoff of 33 pmol/L 
used by the Dutch pediatric study (12), which would falsely classify 21 
patients with sufficient increase in 11-deoxycortisol levels as “adrenal 
insufficient.”
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low morning cortisol, low-dose short synacthen test or 
high-dose short synacthen test. Two Dutch patients did 
allow to be retested, although they used daily hydro-
cortisone (1 based on a CRH test and the other after an 
event during surgery, which at that time was misinter-
preted as an adrenal crisis). In these patients, hydrocor-
tisone was successfully tapered and CAI was excluded 
by MTP.
As Dutch guidelines recommend the use of hydro-
cortisone during physical or psychological stress, 
even in patients without proven CAI, 30 of the 110 
Dutch patients whose medical files were reviewed, re-
ceived hydrocortisone during surgery (without per-
forming an HPA function test first). Eighteen of these 
30 subjects were subsequently formally tested for CAI 
(15 MTP; 3 ITT) and all of them were found to have 
sufficient HPA function, ie, no indication for peri-
operative hydrocortisone. Fifty-three Dutch patients 
had surgery without hydrocortisone, as they were op-
erated before the guidelines were published. None of 
them had any complications during or after surgery. 
Twenty-six of these 53 subjects were subsequently 
tested for CAI (20 MTP; 6 ITT) and all were found 
to be sufficient. None of the 535 non-Dutch patients 
received hydrocortisone stress-dose during illness or 
surgery without undergoing an HPA function test 
(Table 4).
In total, of the 645 patients whose files were reviewed, 
200 underwent surgery without the administration of 
stress doses of hydrocortisone. None of them displayed 
any features of hypocortisolism or adrenal crisis.
Based on ITT and MTP, the prevalence of CAI in the 
82 adults with PWS was 1.2%. Findings from our study 
and those from other groups (10, 12, 15–21) are de-
tailed in Table 5.
Discussion
We tested the HPA axis in 82 adult patients with PWS 
and conclude that CAI is very rare (1.2%) in adults with 
PWS. This low prevalence of CAI is in line with the ma-
jority of studies investigating CAI in people with PWS 
(10, 15–21) (Table 5) but is in sharp contradiction with 
the Dutch pediatric study by De Lind van Wijngaarden 
et al (12), who diagnosed CAI in 60% of Dutch children 
with PWS.
A likely explanation for the discrepancy between the 
Dutch pediatric study and the other studies investigating 
CAI in people with PWS is the difference in the type of 
provocative test used. The different types of provoca-
tive tests used for diagnosing CAI are described in the 
supplementary data (Table S2), which are located in a 
digital data repository (25).Ta
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In the Dutch pediatric study (12), the sMTP was 
used to assess the prevalence of CAI. Patients were 
considered as having CAI when postmetyrapone 
ACTH levels were < 33 pmol/L (150 pg/mL) (26). 
However, a Dutch reference range study (24) showed 
that ACTH levels during sMTP in healthy adult vo-
lunteers ranged from 9.2 to 211.0 pmol/L (42–960 
pg/mL), which suggests that the cutoff used in the 
Dutch pediatric study (<33 pmol/L) is too high, giving 
substantial false-positive results. Other studies have 
also debated the use of ACTH levels in the evalu-
ation of the HPA axis function, as it can lead to 
false-positive results, and recommended that the as-
sessment of CAI should be based on 11-deoxycortisol 
(19, 27). Our study also confirmed the inferiority of 
ACTH cutoff of 33 pmol/L in the interpretation of the 
MTP: 21 of 46 patients who tested sufficient based on 
11-deoxycortisol had peak ACTH levels < 33 pmol/L 
(Fig.  1b). This implies that 45.7% of our patients 
would have tested false-positive and would be given 
hydrocortisone treatment based on the ACTH cutoff 
used in the Dutch pediatric study (12). Some patients 
showed only minimal ACTH increase during MTP, 
whereas their 11-deoxycortisol levels strongly in-
creased (Table 2 and Fig. 1). In 1 patient with a suffi-
cient 11-deoxycortisol response, the ACTH level even 
decreased during MTP. Also, Delta ACTH correlated 
poorly with the 11-deoxycortisol level. These results 
Table 4. Review of medical files of adult patients with Prader–Willi syndrome
Country Patient Files Reviewed (N) Surgery with HC (N) Surgery without HC (N)
Adrenal Crisis During 
Surgery (N)
Italy 240 0 97 0
UK 42 0 13 0
Sweden 38 0 8 0
Spain 45 0 7 0
France 110 0 9 0
Australia 60 1 a 13 0
The Netherlands 110 30 b 53 c 0
Total 645 31 200 0
Abbreviation: HC, hydrocortisone stress dose. 
a The patient had been using daily hydrocortisone after an insufficient low-dose synacthen test. b 2 patients had been using daily hydrocortisone but 
were later tested sufficient; 28 had been using hydrocortisone during operation (16 of them were later tested sufficient). c 26 patients later tested 
sufficient (20 multiple-dose metyrapone test, 6 insulin tolerance test).
Table 5. Summary of studies investigating the prevalence of central adrenal insufficiency in patients with 
Prader–Willi syndrome
Study N Median Age, Years (Range) GH Treatment (%) Testing Method Prevalence (%)
Lind van Wijngaarden, et al  
(2008) (12)
25 9.7 (3.7–18.6) 100 sMTP 60
Connell, et al (2010) (17) 4 7.16 (0.43–16.27) N/A LDSST 4
6 HDSST
15 ITT
Nyunt, et al (2010) (16) 41 7.68 (±5.23) a 46 LDSST 0
Farholt, et al (2011) (18) 58 22 (0.42–48.0) 62 HDSST 0
8 ITT 0
Corrias, et al (2012) (10) 84 7.7 (±5.0) a 63 LDSST 14.2
9 b HDSST 4.8
Grugni, et al (2013) (15) 53 27.9 (18.0–45.2) 30 LDSST 15
6 b HDSST 7.5
Beauloye, et al (2015) (21) 14 4.55 (0.8–14.7) 25 GT 5
7 c 5.6 (3.5–14.4) ITT
Obrynba, et al (2018) (19) 21 d 13.9 (±10.9) a 76 LDSST 29
sMTP 0
Oto, et al (2018) (20) 36 2.0 (0.6–12.0) 0 ITT 0
This study (2019) 46 25.3 (18.1–55.5) 28 MTP 0
36 24.9 (18.0–55.3) ITT 2.8
Abbreviations: GT, glucose tolerance test; HDSST, high-dose synacthen test; ITT, insulin tolerance test; LDSST, low-dose synacthen test; MTP, multiple-
dose metyrapone test; N/A, not available; sMTP, single-dose metyrapone test.
a Age expressed as mean ± SD. b Number of subjects who failed the LDSST and underwent HDSST confirmation test. c 1 subject was tested by GT 
and ITT. d All subjects were tested by LDSST and sMTP. 
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confirm that the ACTH level during the MTP is not a 
reliable parameter to diagnose CAI.
An alternative explanation for the difference in test 
results could be that the MTP suppresses the HPA for 
24 hours, whereas the sMTP, used in the Dutch pediatric 
study, suppresses the HPA only briefly. The administra-
tion of multiple metyrapone doses might give the patient 
more time to produce adequate 11-deoxycortisol levels, 
leading to higher 11-deoxycortisol levels. The sMTP, in 
which metyrapone is administered once at midnight and 
blood samples are collected between 8:00 am and 9:00 
am, might better mimic the real-life situation in which an 
acute event (infection, surgery) requires a fast response 
of the HPA. However, this explanation seems unlikely, 
as CAI prevalences found by our “slow,” multiple-dose 
MTP are equally low as those found during ITT (in 
which there is an acute, short stimulation of the HPA). 
Furthermore, Obrynba et  al, who used the sMTP (re-
quiring a fast response), also found a low prevalence of 
CAI (0%) (19).
Another hypothetical explanation for the low rates 
of CAI in adults compared to children is that all chil-
dren with CAI may have died before reaching adult-
hood. However, based on the incidence of PWS of 
around 1:16.000 live births (28) and the overall death 
rate in PWS of approximately 3% per year (9), this is 
very unlikely. Yearly, 170.000 children are born in the 
Netherlands (Central Bureau for Statistics, 2019)  of 
whom 10 would be expected to have PWS. Thus, in the 
last 55 years, approximately 550 people with PWS are 
likely to have been born. If 60% of the children with 
PWS had CAI and all died before reaching adulthood 
(apart from the regular PWS mortality of 3% per year), 
we would expect only 220 (40% of 550) patients would 
be alive, of which 152 would be adults. However, in 
the Dutch national center of reference, over 110 adults 
with PWS were registered at the moment of submission 
of this manuscript, and we know this is far from the 
total Dutch adult PWS population. Therefore, the as-
sertion that the lower rates of CAI in adults with PWS 
are explained solely by excess mortality due to CAI is 
highly unlikely.
A last theoretical explanation could be the differ-
ence in GH treatment between the Dutch pediatric 
study and our study. In the Dutch pediatric study all 
patients received GH treatment as part of a clinical 
trial, compared to only 28% in our study. This dif-
ference might be relevant as untreated GH deficiency 
may mask CAI. Low insulin-like growth factor I 
(IGF-I) levels result in increased expression and ac-
tivity of 11β-hydroxysteroid dehydrogenase type 1 
(11β-HSD1), the enzyme that converts cortisone to 
cortisol (29). Therefore, untreated GH deficiency 
may result in increased, thus falsely normal, cor-
tisol levels. However, none of our patients had un-
treated GH deficiency, as all patients were tested for 
GH deficiency as part of regular care. Besides, we 
saw no differences in the peak cortisol levels between 
GH-treated patients and non-GH treated patients. 
Furthermore, in a study by Obrynba et al (19), 76% 
of the patients received GH treatment and none of 
them were diagnosed with CAI. This suggests that the 
low CAI prevalence that we found is not explained 
by untreated GH deficiency.
The review of the medical files of 645 adults with 
PWS attending PWS centers worldwide revealed that 
none of the 200 patients who underwent surgery 
without using hydrocortisone displayed any symptoms 
of hypocortisolism or adrenal crisis. This finding is in 
line with the results of the MTP and ITT, demonstrating 
that CAI is virtually absent in adults with PWS.
Only 1 patient was diagnosed with CAI, based on 
a peak cortisol level of 494  nmol/L during the ITT, 
which is just under the cutoff of 500 nmol/L. We cal-
culated the 95% confidence interval (CI) and intra-
assay coefficient of variation (VC) of the cortisol assay 
over 1  year to better understand the significance of 
this borderline-low value. The VC percentage was 6.9 
and the 95% CI was 496 to 504 nmol/L; therefore, in 
the statistical analysis, this single patient was scored 
as having CAI.
To prevent further overtreatment of adults with PWS, 
our results will be implemented in a new guideline on 
the clinical management of adults with PWS. The lack 
of reliability of ACTH in the diagnosis of CAI will also 
be emphasized in the new guidelines.
In conclusion, CAI is very rare (1.2%) in adults with 
PWS. In order to prevent overtreatment with hydrocor-
tisone, we advise against routine hydrocortisone admin-
istration during psychological stress, illness, or surgery 
in adults with PWS. In patients in whom there is a sig-
nificant clinical suspicion of hypocortisolism (such as 
apathy, fainting, or observed hypotension during acute 
infections or other stressful events), we recommend 
testing to exclude CAI and only administer hydrocorti-
sone if CAI is confirmed by ITT or (s)MTP.
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